DGIdb - ERGOCALCIFEROL Drug Record

ERGOCALCIFEROL chembl:CHEMBL1536 Approved

Alternate Names:

VIOSTEROL IN OIL
OSTO-D2
DRISDOL
D-FORTE
STEROGYL 15H
UVESTEROL D
STEROGYL
ERGORAL D2
OLEOVITAMIN D
CALCIFEROL IN ARACH OIL
DELTALIN
ERGO-D2
VITAMIN D
ECIFEROL D2
VITAMIN D 2
LANES
NSC-62792
OLEOVITAMIN D, SYNTHETIC
VITAMIN D2
STEROGYL-15
ERGOCALCIFEROL
CALTRATE
CALCIFEROL
OLEOVITAMIN D2
CRYSTALLINA
ERGOSTEROL IRRADIATED
DECAPS
ERGOCALCIFEROL OIL
ERGOCALCIFEROLUM
(5Z,7E,22E)-(3S)-9,10-SECO-5,7,10(19),22-ERGOSTATETRAEN-3-OL
MINA D2
CALCIFERON 2
CONDOCAPS
D-TRACETTEN
DETALUP
DAVITAMON D
DAVITIN
BETA-OL
CONDOL
CONDACAPS
VIOSTEROL
(+)-VITAMIN D2
HI-DERATOL
ACTIVATED ERGOSTEROL
ERTRON
(5Z,7E,22E)-(3S)-9,10-SECOERGOSTA-5,7,10(19),22-TETRAEN-3-OL
MYKOSTIN
(1S,3Z)-3-{2-[(1R,3AS,4E,7AR)-1-[(2R,3E,5R)-5,6-DIMETHYLHEPT-3-EN-2-YL]-7A-METHYL-OCTAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE}-4-METHYLIDENECYCLOHEXAN-1-OL
DIACTOL
DEE-RONAL
DIVIT URTO
DELTA-TRACETTEN
VIO-D
SYNTHETIC VITAMIN D
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(E,1R,4R)-1,4,5-TRIMETHYLHEX-2-ENYL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-1-CYCLOHEXANOL
METADEE
22-TETRAEN 3BETA 9,10,SECOERGOSTA-5,7,10(19)-OL
UVESTEROL-D
VITAMINA D2
IRRADIATED ERGOSTA-5,7,22-TRIEN-3BETA-OL
DARAL
DERATOL
DE-RAT CONCENTRATE
ERGOCALCIFÉROL
MULSIFEROL
9,10-SECOERGOSTA-5,7,10(19),22-TETRAEN-3B-OL
NOVOVITAMIN-D
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(E,2R,5R)-5,6-DIMETHYLHEPT-3-EN-2-YL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENECYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(E,2R,5R)-5,6-DIMETHYLHEPT-3-EN-2-YL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENE-CYCLOHEXAN-1-OL
DEE-OSTEROL
DELTA-ARTHIN
D-ARTHIN
VIOSTDROL
VITAVEL-D
(3Β,5Z,7E,22E)-9,10-SECOERGOSTA-5,7,10(19),22-TETRAEN-3-OL
DORAL
ERCALCIOL
RODINE C
OSTELIN
SHOCK-FEROL STEROGYL
BUCO-D
ERGOSTEROL ACTIVATED
RADSTERIN
OSTEIL
GELTABS
FORTODYL
DEE-RON
(3BETA,5Z,7E,22E)-9,10-SECOERGOSTA-5,7,10(19),22-TETRAEN-3-OL
(5E,7E,22E)-9,10-SECOERGOSTA-5,7,10,22-TETRAEN-3-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(E,1R,4R)-1,4,5-TRIMETHYLHEX-2-ENYL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-CYCLOHEXAN-1-OL
INFRON
CRTRON
RADIOSTOL
DEE-ROUAL
RADSTEIN
SHOCK-FEROL
VIO D
4-METHYLENE-3-[2-[TETRAHYDRO-7A-METHYL-1-(1,4,5-TRIMETHYL-2-HEXENYL)-4(3AH)-INDANYLIDENE]ETHYLIDENE]-CYCLOHEXANOL
ERGORONE
chemidplus:50-14-6
drugbank:00153
rxcui:4018
pubchem.compound:5280793
chembl:CHEMBL1536

Drug Info:

Drug Class	antihypocalcemic agents
Year of Approval	approved before 1982
FDA Approval	Approved before 1982
Drug Class	small molecule
Drug Indications	Antihypocalcemic Agents

(2 More Sources)

Publications:

Carvallo et al., 2007, The 1alpha,25-dihydroxy Vitamin D3 receptor preferentially recruits the coactivator SRC-1 during up-regulation of the osteocalcin gene., J. Steroid Biochem. Mol. Biol.
Ewing et al., 2007, Novel regulatory role for human Acf1 in transcriptional repression of vitamin D3 receptor-regulated genes., Mol. Endocrinol.
Liu et al., 2006, Expression of vitamin D3 receptor in kidney tumors., Hum. Pathol.
Straube et al., 2010, Vitamin D for the treatment of chronic painful conditions in adults., Cochrane Database Syst Rev
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Jurutka et al., 2007, Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands., J. Bone Miner. Res.
Mikhak et al., 2007, Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk., Prostate
Marks et al., 2007, Transgenic expression of the human Vitamin D receptor (hVDR) in the duodenum of VDR-null mice attenuates the age-dependent decline in calcium absorption., J. Steroid Biochem. Mol. Biol.
Gallagher et al., 2010, Vitamin D insufficiency, deficiency, and bone health., J. Clin. Endocrinol. Metab.

ERGOCALCIFEROL VDR

Interaction Score: 0.44

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Novel drug target Established target

Trial Name -

Mechanism of Interaction Vitamin D receptor agonist

PMIDs:
17218095 17519354 16949927 20091647 11752352 18290715 17440943 17207992 20525913

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
ERGOCALCIFEROL NFE2L2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ERGOCALCIFEROL AR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ERGOCALCIFEROL EHMT2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: ERGOCALCIFEROL
- Version: 01-August-2011
Alternate Names:

ERGOCALCIFEROL Primary Drug Name

Drug Info:

Year of Approval approved before 1982

Drug Class antihypocalcemic agents

Publications:
TdgClinicalTrial: ERGOCALCIFEROL
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Antihypocalcemic Agents

Drug Class small molecule

FDA Approval Approved before 1982

Publications:
DTC: ERGOCALCIFEROL
- Version: 02-September-2020
Alternate Names:

CHEMBL1536 ChEMBL Drug ID

Drug Info:

Publications:
TTD: Ergocalciferol
- Version: 2020.06.01
Alternate Names:

D06JPB TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1536
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1536
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Novel drug target	Established target
Trial Name	-
Mechanism of Interaction	Vitamin D receptor agonist

ERGOCALCIFEROL Drug Record

ERGOCALCIFEROL chembl:CHEMBL1536 Approved

Alternate Names:

Drug Info:

Publications:

ERGOCALCIFEROL VDR

Interaction Types & Directionality: agonist (activating)

Interaction Info: Novel drug target Established target Trial Name - Mechanism of Interaction Vitamin D receptor agonist

PMIDs: 17218095 17519354 16949927 20091647 11752352 18290715 17440943 17207992 20525913

Sources: TdgClinicalTrial ChemblInteractions TEND TTD

ERGOCALCIFEROL NFE2L2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

ERGOCALCIFEROL AR

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

ERGOCALCIFEROL EHMT2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

TEND: ERGOCALCIFEROL

Alternate Names: ERGOCALCIFEROL Primary Drug Name

Drug Info: Year of Approval approved before 1982 Drug Class antihypocalcemic agents

Publications:

TdgClinicalTrial: ERGOCALCIFEROL

Alternate Names:

Drug Info: Drug Indications Antihypocalcemic Agents Drug Class small molecule FDA Approval Approved before 1982

Publications:

DTC: ERGOCALCIFEROL

Alternate Names: CHEMBL1536 ChEMBL Drug ID

Drug Info:

Publications:

TTD: Ergocalciferol

Alternate Names: D06JPB TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1536

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1536

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Novel drug target Established target

Trial Name -

Mechanism of Interaction Vitamin D receptor agonist

PMIDs:
17218095 17519354 16949927 20091647 11752352 18290715 17440943 17207992 20525913

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

ERGOCALCIFEROL Primary Drug Name

Drug Info:

Year of Approval approved before 1982

Drug Class antihypocalcemic agents

Drug Info:

Drug Indications Antihypocalcemic Agents

Drug Class small molecule

FDA Approval Approved before 1982

Alternate Names:

CHEMBL1536 ChEMBL Drug ID

Alternate Names:

D06JPB TTD Drug ID